Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a steroid blast calm kidney stent pain?

NCT ID NCT06930690

Symptom relief Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a high dose of the steroid dexamethasone (20 mg) can reduce urinary symptoms and pain after kidney stone surgery when a temporary stent is placed. About 70 adults will receive either the high dose or a standard dose (4 mg) during surgery and report their symptoms through questionnaires and clinic visits. The goal is to see if the higher dose improves quality of life in the days after the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-70 years old 2. Patients who are undergoing unilateral retrograde ureteroscopy (semi-rigid or flexible) with planned ureteral stent placement for treatment of renal/ureteral stones 3. Patients who can read and understand English 4. Patients who can follow up post-operatively within 7 days at Houston Methodist Hospital Exclusion Criteria: 1. Untreated UTI 2. HbA1c ≥6.5 on preoperative testing 3. Patients with prior diagnosis of any type of diabetes mellitus 4. Patients with immunosuppression, including chronic corticosteroid use 5. Patients with bleeding disorder 6. Patients with chronic liver disease, cirrhosis, and liver failure. 7. Patients taking strong CYP3A4 inducers or inhibitors within two weeks of screening 8. Chronic opioid analgesic use 9. Congenital renal abnormalities (e.g. pelvic kidney, ureteric duplication) that may impair stent placement 10. Concurrent genitourinary malignancy 11. Urinary diversion 12. Renal transplantation 13. History of interstitial cystitis/painful bladder syndrome, prostatitis, pelvic pain due to other conditions (e.g. endometriosis) 14. Neurologic disorder (e.g. spinal cord injury, multiple sclerosis, spina bifida) 15. Pregnant or breastfeeding 16. Patients with cognitive impairments or untreated psychiatric illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ureteral stent-related symptom are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nephrolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ureteral stent-related symptom

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Houston Methodist Hospital

    RECRUITING

    Houston, Texas, 77005, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.